Acute leukemia is a most challenging illness for the oncohematologist because of the high risk of life-threatening complications and the complexity of treatment protocols as well as the uncertain therapeutic outcome, which depends on several host-, disease-and treatment-related factors. When cure is the goal, as is normally the case for fit patients younger than 60 to 65 years with either acute myelogenous leukemia (AML) or acute lymphoblastic leukemia (ALL), 1,2 the general plan is to deliver an intensive multidrug induction and postinduction treatment sequence, in which the greatest intensity, whenever required, is provided by an allogeneic hematopoietic cell transplantation (HCT). For the assessment of treatment response, a set of standard criteria was developed several years ago by a panel of experts, 3 well before the current explosion of sophisticated technologies to assess residual disease status. In accordance, the bone marrow morphology is checked after induction chemotherapy to confirm the achievement of complete remission (CR), which is defined by a marrow blast cell content of less than 5%, together with the recovery of normal blood cell counts.
Whereas CR is the mandatory first step of the process leading to cure, more recent technology allows the identification of submicroscopic amounts of leukemic cells in the bone marrow of patients in CR, referred to as minimal residual disease (MRD), which goes undetected by light microscopy (one leukemic cell out of 10,000 to 100,000 cells) but nevertheless exerts a strong and independent prognostic impact, greatly increasing the risk of a patient experiencing an early relapse.
HCT is a powerful therapeutic modality commonly prescribed to younger patients in CR with intermediate-and high-risk characteristics. HCT is favored because of its superior activity compared with non-HCToptions, both within and outside clinical trials, and it has had little change in treatment strategy over the past decades. 4, 5 Having become standard practice in many developed countries, the number of HCTs performed has grown steadily, as demonstrated by the more than 40,000 and 20,000 HCTs performed worldwide in patients with AML and ALL, respectively, between 2006 and 2014. 6 This treatment burden is unavoidable and reflects established indications and our wish to cure as many patients as possible; yet, the economic costs generated by the procedure itself as well as the management of the many related acute and chronic toxicities-and above all the associated risk of transplant-related mortality (TRM), averaging slightly below 10%, but higher in many published series-are great. To emphasize this point, a minimum of 6,000 TRMs are expected from a total of 60,000 HCTs, which is clearly an issue for the transplant team and any public health system, given that the estimated average cost of the procedure exceeds $200,000 US at day 100, only to rise progressively. 7, 8 Apart from these concerns, HCT still is, and will long remain, necessary to cure many patients who cannot be cured with chemotherapy, until the promises of novel, targeted therapies are fulfilled, which, to date, has occurred only in acute promyelocytic leukemia.
9 Therefore, the clarification of any issue associated with the risk of transplantation failure, that is, recurrence or TRM, can only improve transplantation strategy and use of available resources, leading eventually to an overall therapeutic benefit.
The article by Araki et al 10 that accompanies this editorial is another relevant contribution from the Fred Hutchinson Cancer Research Center (Seattle, WA) on the relationship between CR status, reassessed through MRD analysis, and the outcome of 359 patients with AML who received myeloablative HCTs. With the MRD study performed prior to HCT by using a 10-color, multiparametric flow cytometry, Araki et al 10 demonstrate that not all CRs are the same, and that the likelihood of post-transplantation success varies significantly by function of CR status and MRD as well. In fact, among patients in CR, the relapse rate was only 22% in the MRD-negative group compared with 67% in MRD-positive patients in CR and 65% in patients not in CR, and an MRD positivity of 0.1% or greater (or lower in some patients) retained a high, independent predictive power for relapse in multivariable comparisons with all other risk factors.
The direct relationship between MRD and relapse risk was clearly evident in the large, well-performed clinical study by Araki et al. 10 For several reasons, it is becoming difficult to ignore MRD in patients in CR with a risk profile that requires an HCT to reach cure, and these include the fact that MRD is a sensitive, patientspecific risk indicator, it is also rather inexpensive and relatively easy to assess, and it provides added information beyond standard cytogenetic risk class and underlying genetic abnormalities. In addition to improving the definition and the clinico-prognostic meaning of a CR status, now labeled as either MRD negative or MRD positive, these results prompt completely new clinical studies and, perhaps, a new transplantation strategy, as clearly stated by the authors: "patients with active AML could be combined with patients in MRD-positive remission who have a similarly high disease risk in trials aimed primarily at reducing the risk of post-transplant relapse. In contrast, patients in MRDnegative remission would be suitable for prospective, controlled studies evaluating whether lower-intensity allogeneic HCTor other treatment modalities, such as autologous HCT or non-HCT therapies, could further improve outcomes in these lower-risk patients." 10(p333) If new strategies form around HCT, the evidence in favor of an MRD study in AML is compelling. Studies would start from the first few days of induction, 11 going through to the critical postinduction assessment of CR 12 and midconsolidation, 13 with proven value not only in adults but also in children, where the decisional criteria about whether to proceed to HCT acquire even greater relevance, 14 and the elderly. 15 The growing importance of MRD in AML is similar to the importance that MRD has achieved in ALL, a disease for which MRD is crucial in refining the individual risk class and in decisions regarding HCT, which has been reviewed in detail. 16, 17 Several prospective trials of risk-oriented therapy on the basis of MRD were performed in patients with ALL, which permitted the selective use of HCT in high-risk, MRD-positive patients, [18] [19] [20] and achieved survival rates of up to 50% in adults. Results were significantly better in MRD-negative patients who were treated conservatively with chemotherapy only (survival was 65% to 80% in adults and 90% and greater in children). Moreover, in patients with ALL, MRD is an ideal therapeutic objective for novel targeted therapies. This was documented by a first successful trial with the bispecific, anti-CD3/CD19 construct blinatumomab in MRD-positive Bprecursor ALL, 21 and is being investigated in several other studies introducing innovative T-and NK-cell-based antileukemic strategies, some of which are reporting exceptional early results.
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In summary, MRD has profoundly influenced our treatment approach for acute leukemia, permitting a better definition of CR and risk class, and favoring a better risk-adapted treatment strategy that is increasingly oriented to spare the risk of TRM and other transplantation morbidity in younger patients with optimal MRD response. Furthermore, it has allowed the separation among the MRD-positive patients of those who are curable by HCT from those who are not and who are preferably transferred to experimental therapies. There are limitations and pitfalls, of course, concerning methods, definitions, and the timing of MRD analysis to obtain clinically generalizable results. Regarding MRD methods and definitions, whereas multiparametric flow cytometry was used in all AML studies examined, the molecular analysis is highly suitable for many disease subsets 23 and seems to be more sensitive in patients with ALL, where it allows a precise definition of MRD response in CR patients (molecular CR v failure). 24 For timing of MRD analysis, early postinduction time points are informative in ALL and also correlate with post-transplantation outcome, 16, 17, 19, 20 whereas this is presently less certain in AML and efforts toward standardization are warranted. Relative to pretransplantation MRD, it is worth noting that a successful late transplantation in consolidated MRD-negative patients with AML, that is, after 6 to 12 months from CR (some cases in the study by Araki et al 10 ), may represent a misleading, albeit positive, therapeutic result. This is because some of these patients might be cured by prior chemotherapy, particularly if patients test negative for MRD soon after achieving CR and prior to HCT. This bias should be addressed by new trials designed with predefined MRD time points from CR to HCT, and with a time-dependent analysis of HCT results. 20 The time has come to close the gap between AML and ALL, for which MRD is already an essential part of a highly personalized treatment. 25 The information added by Araki et al 10 radically alters the perception we have of CR status at the time of HCT, introducing MRD as a critical predictor of outcome, similar to what is known for ALL. On recognizing the value of this work, 10 and to place it in the context of the many achievements promoted by the pioneer of HCT, Nobel Laureate E. Donnall Thomas (1920 to 2012) and his associates at the Fred Hutchinson Cancer Research Center, there is a new chance to improve treatment and transplantation strategies in patients with AML and ALL.
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